• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/6/25 6:48:51 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    kvue-20250206
    0001944048false00019440482025-02-062025-02-06

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): February 6, 2025
    Kenvue Inc.
     (Exact name of registrant as specified in its charter)
    Delaware001-4169788-1032011
    (State or other jurisdiction
     of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    199 Grandview Road
    Skillman, New Jersey
    08558
    (Address of principal executive offices)(Zip Code)
    Registrant's telephone number, including area code: (908)-874-1200
    Not applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.01 par value per shareKVUENew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02     Results of Operations and Financial Condition
     
    On February 6, 2025, Kenvue Inc. issued the attached press release (Exhibit 99.1) announcing its financial results for the fiscal full year and fourth quarter ended December 29, 2024.

    The information contained under Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
     
    Item 9.01    Financial Statements and Exhibits

    (d)     Exhibits. 
     
    Exhibit NumberExhibit Description
    99.1
    Press Release dated February 6, 2025 for the period ended December 29, 2024
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    KENVUE INC.
    Date: February 6, 2025
    By:/s/ Paul Ruh
      Name:
    Title:
    Paul Ruh
    Chief Financial Officer

    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader

    Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

    11/3/25 6:30:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    Kenvue Reports Third Quarter 2025 Results

    Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th

    11/3/25 6:30:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    10/29/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Redburn Atlantic initiated coverage on Kenvue with a new price target

    Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

    4/10/25 12:41:58 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    SEC Form 425 filed by Kenvue Inc.

    425 - Kenvue Inc. (0001944048) (Subject)

    12/10/25 5:21:26 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 425 filed by Kenvue Inc.

    425 - Kenvue Inc. (0001944048) (Subject)

    12/10/25 5:07:47 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 425 filed by Kenvue Inc.

    425 - Kenvue Inc. (0001944048) (Subject)

    12/3/25 5:22:46 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith Jeffrey C

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/3/25 5:30:08 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    General Counsel Orlando Matthew converted options into 4,378 shares and covered exercise/tax liability with 2,031 shares, increasing direct ownership by 9% to 28,839 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/3/25 5:06:48 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Hofstetter Sarah

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/3/25 5:06:54 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader

    Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

    11/3/25 6:30:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    Kenvue Reports Third Quarter 2025 Results

    Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th

    11/3/25 6:30:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    10/29/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary